Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
Tóm tắt
Repurposing of existing drugs and drug candidates is an ideal approach to identify new potential therapies for SARS-CoV-2 that can be tested without delay in human trials of infected patients. Here we applied a virtual screening approach using Autodock Vina and molecular dynamics simulation in tandem to calculate binding energies for repurposed drugs against the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). We thereby identified 80 promising compounds with potential activity against SARS-Cov2, consisting of a mixture of antiviral drugs, natural products and drugs with diverse modes of action. A substantial proportion of the top 80 compounds identified in this study had been shown by others to have SARS-CoV-2 antiviral effects in vitro or in vivo, thereby validating our approach. Amongst our top hits not previously reported to have SARS-CoV-2 activity, were eribulin, a macrocyclic ketone analogue of the marine compound halichondrin B and an anticancer drug, the AXL receptor tyrosine kinase inhibitor bemcentinib. Our top hits from our RdRp drug screen may not only have utility in treating COVID-19 but may provide a useful starting point for therapeutics against other coronaviruses. Hence, our modelling approach successfully identified multiple drugs with potential activity against SARS-CoV-2 RdRp.
Tài liệu tham khảo
Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331–5. https://doi.org/10.1126/science.abb4489.
Zhu W, Chen CZ, Gorshkov K, Xu M, Lo DC, Zheng W. RNA-dependent RNA polymerase as a target for COVID-19 drug discovery. SLAS Discov. 2020;25(10):1141–51. https://doi.org/10.1177/2472555220942123.
Guterres H, Im W. Improving protein-ligand docking results with high-throughput molecular dynamics simulations. J Chem Inf Model. 2020;60(4):2189–98. https://doi.org/10.1021/acs.jcim.0c00057.
Winkler DA. Ligand entropy is hard but should not be ignored. J Chem Inf Model. 2020;60(10):4421–3. https://doi.org/10.1021/acs.jcim.0c01146.
Beg MA, Athar F. Anti-HIV and anti-HCV drugs are the putative inhibitors of RNA-dependent-RNA polymerase activity of nsp12 of the SARS-CoV- 2 (COVID-19). Pharm Pharmacol Int J. 2020;8(3):163–72. https://doi.org/10.15406/ppij.2020.08.00292.
Cozac R, Medzhidov N, Yuki S. Predicting inhibitors for SARS-CoV-2 RNA-dependent RNA polymerase using machine learning and virtual screening}. arXiv. 2020:2006.06523.
Dutta K, Shityakov S, Morozova O, Khalifa I, Zhang J, Zhu W, et al. Beclabuvir can inhibit the RNA-dependent RNA polymerase of newly emerged novel coronavirus (SARS-CoV-2). Preprints. 2020:2020030395. https://doi.org/10.20944/preprints202003.0395.v2.
Shannon A, Le NT, Selisko B, Eydoux C, Alvarez K, Guillemot JC, et al. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antivir Res. 2020;178:104793. https://doi.org/10.1016/j.antiviral.2020.104793.
Anastasiou IA, Eleftheriadou I, Tentolouris A, Tsilingiris D, Tentolouris N. In vitro data of current therapies for SARS-CoV-2. Curr Med Chem. 2020;27(27):4542–8. https://doi.org/10.2174/0929867327666200513075430.
Dyer O. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. Br Med J. 2020;371:m4057. https://doi.org/10.1136/bmj.m4057.
Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592. https://doi.org/10.1016/j.lfs.2020.117592.
Ahmed S, Mahtarin R, Ahmed SS, Akter S, Islam MS, Mamun AA, et al. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2. J Biomol Struct Dyn. 2020:1–16. https://doi.org/10.1080/07391102.2020.1796804.
Aouidate A, Ghaleb A, Chtita S, Aarjane M, Ousaa A, Maghat H, et al. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation. J Biomol Struct Dyn. 2020;39(12):1–14. https://doi.org/10.1080/07391102.2020.1779130.
Banerjee S, Dey R, Seal S, Mondal KK, Bhattacharjee P. Identification of best suitable repurposed drugs considering mutational spectra at RdRp (nsp12), 3CLpro (nsp5) and PLpro (nsp3) of SARS-CoV-2 in indian population. Res Square. 2020. https://doi.org/10.21203/rs.3.rs-33879/v1.
Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020;73(9):593–602. https://doi.org/10.1038/s41429-020-0336-z.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020;178:104787. https://doi.org/10.1016/j.antiviral.2020.104787.
Dixit A, Yadav R, Singh AV. Ivermectin: Potential role as repurposed drug for COVID-19. Malays J Med Sci. 2020;27(4):154–158. https://doi.org/10.21315/mjms2020.27.4.15
Daghir Janabi AH. Effective anti-SARS-CoV-2 RNA dependent RNA polymerase drugs based on docking methods: The case of milbemycin, ivermectin, and baloxavir marboxil. Avicenna J Med Biotechnol. 2020;12(4):246–50. https://www.ncbi.nlm.nih.gov/pubmed/33014317. Published 2020/10/06.
Kalhor H, Sadeghi S, Abolhasani H, Kalhor R, Rahimi H. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 s protein and human ACE2 interaction through virtual screening approaches. J Biomol Struct Dyn. 2020:1–16. https://doi.org/10.1080/07391102.2020.1824816.
Cho J, Lee YJ, Kim JH, Kim SI, Kim SS, Choi BS, et al. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. npj Sci Rep. 2020;10(1):16200. https://doi.org/10.1038/s41598-020-72879-7.
Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819–20. https://doi.org/10.1128/AAC.00819-20.
Bosch-Barrera J, Martin-Castillo B, Buxo M, Brunet J, Encinar JA, Menendez JA. Silibinin and SARS-CoV-2: dual targeting of host cytokine storm and virus replication machinery for clinical management of COVID-19 patients. J Clin Med. 2020;9(6):1770. https://doi.org/10.3390/jcm9061770.
Pokhrel R, Chapagain P, Siltberg-Liberles J. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2. J Med Microbiol. 2020;69(6):864–73. https://doi.org/10.1099/jmm.0.001203.
Ahmad J, Ikram S, Ahmad F, Rehman IU, Mushtaq M. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) - a drug repurposing study. Heliyon. 2020;6(7):e04502. https://doi.org/10.1016/j.heliyon.2020.e04502.
Imami AS, O'Donovan SM, Creeden JF, Wu X, Eby H, McCullumsmith CB, et al. Oxytocin’s anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach. Physiol Genomics. 2020;52(9):401–7. https://doi.org/10.1152/physiolgenomics.00095.2020.
Machitani M, Yasukawa M, Nakashima J, Furuichi Y, Masutomi K. RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19. Cancer Sci. 2020;111(11):3976–84. https://doi.org/10.1111/cas.14618.
Choudhury S, Moulick D, Saikia P, Mazumder MK. Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach. Med J Arm Forc India. 2020: in press. https://doi.org/10.1016/j.mjafi.2020.05.005.
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, et al. Comprehensive analysis of drugs to treat sarscov2 infection: mechanistic insights into current covid19 therapies (review). Int J Mol Med. 2020;46(2):467–88. https://doi.org/10.3892/ijmm.2020.4608.
Chandra A, Gurjar V, Qamar I, Singh N. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19, Journal of Biomolecular Structure and Dynamics. 2021;39(12):4201-11. https://doi.org/10.1080/07391102.2020.1775127.
Care UoIH. University of iowa virology research helps facilitate new clinical trial for COVID-19. Published 2020. https://www.eurekalert.org/pub_releases/2020-04/uoih-uoi042920.php. Accessed 7 Mar 2021
Liu S, Lien CZ, Selvaraj P, Wang TT. Evaluation of 19 antiviral drugs against SARS-CoV-2 infection. bioRxiv. 2020:2020.04.29.067983. doi:https://doi.org/10.1101/2020.04.29.067983.
Dittmar M, Lee JS, Whig K, Segrist E, Li M, Jurado K, et al. Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2. bioRxiv. 2020:2020.06.19.161042. https://doi.org/10.1101/2020.06.19.161042.
Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. bioRxiv. 2020:2020.06.22.165712. https://doi.org/10.1101/2020.06.22.165712.
Yamamoto N, Matsuyama S, Hoshino T, Yamamoto N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv. 2020:2020.04.06.026476. https://doi.org/10.1101/2020.04.06.026476.
Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021;93(3):1403–8. https://doi.org/10.1002/jmv.26397.
Milani M, Donalisio M, Bonotto RM, Schneider E, Arduino I, Boni F, et al. Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and hcov-oc43 inhibitors. bioRxiv. 2020:2020.11.12.379958. https://doi.org/10.1101/2020.11.12.379958.
Vatansever EC, Yang K, Kratch KC, Drelich A, Cho C-C, Mellot DM, et al. Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19. bioRxiv. 2020:2020.05.23.112235. https://doi.org/10.1101/2020.05.23.112235.
Van Damme E, De Meyer S, Bojkova D, Ciesek S, Cinatl J, De Jonghe S, et al. In vitro activity of itraconazole against SARS-CoV-2. bioRxiv. 2020:2020.11.13.381194. https://doi.org/10.1101/2020.11.13.381194.
Nakajima K, Ogawa F, Sakai K, Uchiyama M, Oyama Y, Kato H, et al. A case of coronavirus disease 2019 treated with ciclesonide. Mayo Clin Proc. 2020;95(6):1296–7. https://doi.org/10.1016/j.mayocp.2020.04.007.
Sales-Medina DF, Ferreira LRP, Romera LMD, Gonçalves KR, Guido RVC, Courtemanche G, et al. Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19. bioRxiv. 2020:2020.07.09.196337. https://doi.org/10.1101/2020.07.09.196337.
Rothlin RP, Vetulli HM, Duarte M, Pelorosso FG. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res. 2020;81(7):768–70. https://doi.org/10.1002/ddr.21679.
Lo HS, Hui KPY, Lai H-M, Khan KS, Kaur S, Li Z, et al. Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir. bioRxiv. 2020:2020.05.26.116020. https://doi.org/10.1101/2020.05.26.116020.
Drayman N, Jones KA, Azizi S-A, Froggatt HM, Tan K, Maltseva NI, et al. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <em>in vitro</em>. bioRxiv. 2020:2020.08.31.274639. https://doi.org/10.1101/2020.08.31.274639.
Weston S, Haupt R, Logue J, Matthews K, Frieman MB. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. bioRxiv. 2020:2020.03.25.008482. https://doi.org/10.1101/2020.03.25.008482.
Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, et al. Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2. bioRxiv. 2020:2020.07.06.188953. https://doi.org/10.1101/2020.07.06.188953.
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. https://doi.org/10.1002/jcc.20084.
Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the autodock suite. Nat Protoc. 2016;11(5):905–19. https://doi.org/10.1038/nprot.2016.051.
Laskowski RA, Swindells MB. Ligplot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51(10):2778–86. https://doi.org/10.1021/ci200227u.
Zoete V, Cuendet MA, Grosdidier A, Michielin O. Swissparam: a fast force field generation tool for small organic molecules. J Comput Chem. 2011;32(11):2359–68. https://doi.org/10.1002/jcc.21816.
Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hessa B, et al. GROMACS; high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. https://doi.org/10.1016/j.softx.2015.06.001.
Paissoni C, Spiliotopoulos D, Musco G, Spitaleri A. GMXPBSA 2.1: a GROMACS tool to perform MM/PBSA and computational alanine scanning. Comp Phys Comm. 2015;186:105–7. https://doi.org/10.1016/j.cpc.2014.09.010.
Baker NA, Sept D, Holst MJ, McCammon JA. The adaptive multilevel finite element solution of the poisson-boltzmann equation on massively parallel computers. IBM J Res Devel. 2001;45(3.4):427–38. https://doi.org/10.1147/rd.453.0427.